To determine to what extent hyperglycemia contributes to the transient lipodystrophy and metabolic syndrome in Ai-DKO mice, we treated mice with the SGLT2 inhibitor remogliflozin (Remo). This evidence concerns the gene SLC5A2 and lipodystrophy.